Intelligent Ultrasound Group PLC Notice of Results (9723S)

TIDMIUG

RNS Number : 9723S

Intelligent Ultrasound Group PLC

15 March 2023

Intelligent Ultrasound Group plc

(the "Group" or the "Company")

Notice of results

Analyst and investor briefing

Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company, specialising in artificial intelligence (AI) software and simulation, announces it will issue its preliminary results for the year ended 31 December 2022 on Thursday, 20 April 2023.

A briefing for analysts will be held via Zoom on 20 April 2023 at 9.30am. To register, please contact Walbrook PR at [e-mail] .

The Company will host a live presentation for investors given by Stuart Gall and Helen Jones via the Investor Meet Company platform on Thursday, 20 April 2023 at 2.15pm. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet the Company via: https://www.investormeetcompany.com/intelligent-ultrasound-group-plc/register-investor

Investors who already follow Intelligent Ultrasound on the Investor Meet Company platform will automatically be invited.

Separately, the Company announces an investor day at their headquarters in Cardiff. This will take place on Tuesday, 25 April 2023 and will include an overview of the business and a live demonstration of the products. For further details and to register to attend, please contact [e-mail] or call 020 7397 8900.

For further information, please contact:

 
Intelligent Ultrasound Group                                                     www. intelligentultrasound.com 
 plc 
Stuart Gall, CEO                                                                       Tel: [phone] 
Helen Jones, CFO 
 
 
Cenkos Securities - Nominated Advisor                                                  Tel: [phone] 
 and Broker 
Giles Balleny / Max Gould (Corporate 
 Finance) 
Michael Johnson / Julian Morse 
 (Sales) 
 
 
Walbrook PR                                    Tel: [phone] or [e-mail] 
Anna Dunphy                                                                            Mob: [phone] 
 
 

ABOUT INTELLIGENT ULTRASOUND GROUP

Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to clinic' ultrasound companies, specialising in real-time hi-fidelity virtual reality simulation for the ultrasound training market ('classroom') and artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market ('clinic'). Based in Cardiff in the UK and Atlanta in the US, the Group has two revenue streams:

Simulation

Real-time hi-fidelity ultrasound education and training through simulation. Our main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eve Point of Care and Emergency Medicine training simulator with Covid-19 module and the new BabyWorks Neonate and Paediatric training simulator. To date over 1,450 simulators have been sold to over 700 medical institutions around the world.

Clinical AI software

Deep learning-based algorithms to make ultrasound machines smarter and more accessible using our proprietary ScanNav ultrasound image analysis technology. Current products on the market utilising this technology are GE Healthcare's SonoLyst software that is incorporated in their Voluson Expert 22 and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies ultrasound image interpretation by providing the user with real-time AI-based anatomy highlighting for a range of ultrasound guided regional anesthesia procedures; and NeedleTrainer that teaches real-time ultrasound-guided needling and incorporates ScanNav Anatomy PNB.

www.intelligentultrasound.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORDZGMFNDFGFZM

(END) Dow Jones Newswires

March 15, 2023 03:00 ET (07:00 GMT)